Yokoyama T, Yoshioka H, Fujimoto D, et al. - In patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), researchers evaluated the effectiveness and safety of low starting dose of afatinib with dose modification according to its toxicity. For this multicenter, single-arm, open-label phase II trial, treatment-naïve patients with advanced NSCLC positive for common EGFR mutations took afatinib starting in a dose of 20 mg/day. The dose was risen in increments of 10 mg up to 50 mg/day if tolerated. Forty-six patients [median age was 73 years (range, 43–86)] were enrolled from February 2015 through March 2016. Data reported that the median progression-free survival was 15.2 months and the 1-year overall survival rate was 95.6%. Overall, the authors concluded that a low starting dose of afatinib treatment demonstrated promising clinical effectiveness and excellent tolerability. Rash/acne, paronychia, diarrhea were the reported adverse events. There has been no death related to treatment.